Table 2 Overall sequencing of biologic drug switches
Anti-TNFα | Rituximab | Tocilizumab | Abatacept | Total | |
|---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | n (%) | |
Anti-TNFα | 84 (25.1) | 172 (51.3) | 21 (6.3) | 10 (3.0) | 287 (85.7) |
n (%) | |||||
Rituximab | 15 (4.4) | - | 26 (7.8) | 4 (1.2) | 45 (13.4) |
n (%) | |||||
Tocilizumab | 0 (0) | 1 (0.3) | - | 2 (0.6) | 3 (0.9) |
n (%) | |||||
Abatacept | 0 (0) | 0 (0) | 0 (0) | - | 0 (0) |
n (%) | |||||
Total | 99 (29.6) | 173 (51.6) | 47 (14.0) | 16 (4.8) | 335 (100) |
n (%) |